We analyze all significant studies concerning the use of Ivermectin for COVID-19. Search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), all individual study data, PRISMA answers, and statistical methods are detailed in Appendix 1. We present random effects meta-analysis results for all studies, for studies within each treatment stage, for mortality results, for COVID-19 case results, for viral clearance results, for peer-reviewed studies, for Randomized Controlled Trials (RCTs), and after exclusions.
We also perform a simple analysis of the distribution of study effects. If treatment was not effective, the observed effects would be randomly distributed (or more likely to be negative if treatment is harmful). We can compute the probability that the observed percentage of positive results (or higher) could occur due to chance with an ineffective treatment (the probability of >= k heads in n coin tosses, or the one-sided sign test / binomial test). Analysis of publication bias is important and adjustments may be needed if there is a bias toward publishing positive results.
Read More https://ivmmeta.com/?fbclid=IwAR2O5S07pvsztdOofVg6YINCNxR-t1o1WPyAZ_vMmariKjeNQHbFxTbinbM#intro
image: A box of Ivermectine, made by Biogaran, at a counter of a pharmacy in Paris, France. Photo by: Benoit Tessier / Reuters